These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24818338)

  • 1. Treatment with DPP-4 inhibitors does not increase the chance of pancreatitis in patients with type 2 diabetes.
    Shetty AS; Nandith A; Snehalath C; Ramachandran A
    J Assoc Physicians India; 2013 Aug; 61(8):543-4. PubMed ID: 24818338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting.
    Lando HM; Alattar M; Dua AP
    Endocr Pract; 2012; 18(4):472-7. PubMed ID: 22440997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.
    Iyer SN; Drake AJ; West RL; Mendez CE; Tanenberg RJ
    Endocr Pract; 2012; 18(1):e10-3. PubMed ID: 22068258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
    Engel SS; Williams-Herman DE; Golm GT; Clay RJ; Machotka SV; Kaufman KD; Goldstein BJ
    Int J Clin Pract; 2010 Jun; 64(7):984-90. PubMed ID: 20412332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
    Mikhail N
    Vasc Health Risk Manag; 2008; 4(6):1221-7. PubMed ID: 19337535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.
    Ayaori M; Iwakami N; Uto-Kondo H; Sato H; Sasaki M; Komatsu T; Iizuka M; Takiguchi S; Yakushiji E; Nakaya K; Yogo M; Ogura M; Takase B; Murakami T; Ikewaki K
    J Am Heart Assoc; 2013 Jan; 2(1):e003277. PubMed ID: 23525426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes.
    Maeda H; Kubota A; Tanaka Y; Terauchi Y; Matsuba I;
    Diabetes Res Clin Pract; 2012 Jan; 95(1):e20-2. PubMed ID: 22055835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.
    Richter B; Bandeira-Echtler E; Bergerhoff K; Lerch C
    Vasc Health Risk Manag; 2008; 4(4):753-68. PubMed ID: 19065993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.
    Aso Y; Ozeki N; Terasawa T; Naruse R; Hara K; Suetsugu M; Takebayashi K; Shibazaki M; Haruki K; Morita K; Inukai T
    Transl Res; 2012 Jan; 159(1):25-31. PubMed ID: 22153807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
    Aaboe K; Akram S; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2015 Jan; 17(1):74-81. PubMed ID: 25243647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study.
    Hong ES; Khang AR; Yoon JW; Kang SM; Choi SH; Park KS; Jang HC; Shin H; Walford GA; Lim S
    Diabetes Obes Metab; 2012 Sep; 14(9):795-802. PubMed ID: 22443183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLP-1-based therapies: the dilemma of uncertainty.
    Spranger J; Gundert-Remy U; Stammschulte T
    Gastroenterology; 2011 Jul; 141(1):20-3. PubMed ID: 21723985
    [No Abstract]   [Full Text] [Related]  

  • 13. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
    Elashoff M; Matveyenko AV; Gier B; Elashoff R; Butler PC
    Gastroenterology; 2011 Jul; 141(1):150-6. PubMed ID: 21334333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of concomitant drugs on sitagliptin-mediated improvement in glycemic control in Japanese patients with type 2 diabetes.
    Hirata T; Inukai K; Morimoto J; Katayama S; Ishida H
    Prim Care Diabetes; 2014 Oct; 8(3):265-70. PubMed ID: 24530100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.
    Hanefeld M; Herman GA; Wu M; Mickel C; Sanchez M; Stein PP;
    Curr Med Res Opin; 2007 Jun; 23(6):1329-39. PubMed ID: 17559733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
    Aston-Mourney K; Subramanian SL; Zraika S; Samarasekera T; Meier DT; Goldstein LC; Hull RL
    Am J Physiol Endocrinol Metab; 2013 Aug; 305(4):E475-84. PubMed ID: 23736544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
    Richter B; Bandeira-Echtler E; Bergerhoff K; Lerch CL
    Cochrane Database Syst Rev; 2008 Apr; 2008(2):CD006739. PubMed ID: 18425967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature.
    Furukawa S; Kumagi T; Miyake T; Ueda T; Niiya T; Nishino K; Murakami S; Murakami M; Matsuura B; Onji M
    Endocr J; 2012; 59(4):329-33. PubMed ID: 22277726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
    Scheen AJ
    Diabetes Metab; 2012 Apr; 38(2):89-101. PubMed ID: 22197148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.